5. For females of child- bearing potential, negative serum pregnancy test at screening (within 48 hours prior to leukapheresis). Pro00054746: RESIST Study Version: 20171011 PT-PhI-II v05.22.12 Duke Cancer Institute Page 28 CONFIDENTIAL 6. Women of childbearing potential and male participants must agree to practice adequate contraception. 7. KPS of ≥ 70. 8. CBC/differential with adequate bone marrow function as defined below within 2 weeks of enrollment: a) Absolute neutrophil count, ≥ 1500 cells/mm 3. b) Platelet count, ≥ 100,000 cells/mm3. c) Hemoglobin ≥ 10 g/dl. (Note: the use of transfusion or other intervention to achieve Hgb ≥ 10 g/dl is acceptable.) 9. Adequate renal function as defined below within 2 weeks of enrollment: a) BUN ≤ 25 mg/dl. b) Creatinine ≤ 1.7 mg/dl. 10. Adequate hepatic function as defined below within 2 weeks of enrollm ent: a) Bilirubin ≤ 2.0 mg/dl. b) ALT ≤ 3 x normal range. c) AST ≤ 3 x normal range. 11.2 Exclusion Criteria 1. Prior invasive malignancy (except for non- melanomatous skin cancer) unless disease free for ≥ 3 years. (For example, carcinoma in situ of the breast, oral cavity , and cervix are all permissible.) 2. Metastases detected below the tentorium or beyond the cranial vault . 3. Severe, active co- morbidity, defined as follows: a. Unstable angina and/or congestive heart failure requiring hospitalization. b. Myocardial infarction within the last 6 months. c. Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol . The need to exclude patients with AIDS from this protocol is necessary because t reatments involved in this protocol may be significantly immunosuppressive. d. Major medical illnesses or psychiatric impairments that in the investigator's opinion will prevent administration or completion of protocol therapy. 4. Pregnant or lactating women, due to possible adverse effects on the developing fetus or infant due to study drug. 5. Prior allergic reaction to temozolomide. 6. Patients treated on any other therapeutic clinical protocols within 30 days prior to study entry or during participation in the stud y. 7. Patients with known hypersensitivity to GM- CSF, yeast -derived products, or any component of Leukine®. 8. Allergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccine. 9.